BioCentury
ARTICLE | Strategy

Teva: No more silos

How new R&D head Hayden plans to remake Teva's discovery, global partnering

May 14, 2012 7:00 AM UTC

Teva Pharmaceutical Industries Ltd.'s new CSO and president of global R&D, Michael Hayden, plans to break down the silos housing generics and branded R&D with the aim of improving both businesses while better serving a global patient population.

He also has designs on increasing in-house discovery and personalized medicines efforts, and on opening up the organization to more innovative partnering...